Business
SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results
Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company. Full year 2024 revenues were $32.6 million,
About this update from Sanuwave Health, Inc.
[{"type":"text","content":"Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company. Full year 2024 revenues were $32.6 million, up 60% from full year 2023 revenues. This was an all-time annual record for the Company. Q4 2024 gross margin was 77.9%, versus 69.1% in Q4 2023 and 75.5% in Q3 2024. Full year 2024 gross margin was 75.2% versus 70.4% in 2023. GAAP Operating Income was $2.5 million for Q4 2024 and $5.4 million for full year 2024. Company provides guidance for revenue growth of 45-55% for Q1 2025 as compared to Q1 2024 and initiates full year 2025 revenue guidance of $48-50 million for full year 2025 (an increase of 47-53% versus 2024) EDEN PRAIRIE, Minn., March 21, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the \"Company\" or \"Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months and for the full year ended December 31, 2024. Q4 2024 ended December 31, 2024 Revenue for the three months ended December 31, 2024, totaled $10.3 million, an increase of 47%, as compared to $7.0 million for the same period of 2023. This growth is consistent with guidance of growth of 40-50% year on year for the quarter.135 UltraMist® systems were sold in Q4 2024 up from 79 in Q4 2023 and from 124 in Q3 2024.UltraMist® consumables revenue increased by 59% to $5.9 million in Q4 2024 versus $3.7 million for the same quarter last year. Consumables revenue represented 58% of overall revenues in Q4 2024. UltraMIST systems and consumables remained the primary revenue growth driver for the Company and represented over 99% of SANUWAVE’s overall revenues in Q4 2024.Gross margin as a percentage of revenue amounted to 77.9% for the three months ended December 31, 2024, versus 69.1% for the same period last year.For the three months ended December 31, 2024, operating income totaled $2.5 million, an increase of $1.5 million, or 143%, compared to Q4 2023, primarily as a result of the Company’s continued efforts to drive profitable growth and manage expenses.Net loss for the fourth quarter of 2024 was $12.7 million, driven predominantly by the change in the fair value of derivative liabilities, valuation adjustments resulting from the share and warrant exchange, and the extinguishment of debt. This compares to a net ...